Global X Funds (NYSEARCA:GREK) shares are up 3.4% in pre-market trading to $9.
Mizuho analyst Peter Lawson weighed in with some commentary on Kite Pharma Inc (NASDAQ:KITE) following the company’s Investor Day. The analyst reiterated an Outperform …
Kite Pharma Inc (NASDAQ:KITE) and bluebird bio, Inc. announced that they have entered into a collaboration agreement to co-develop and co-commercialize second generation T …
Maxim Group analyst Jason McCarthy initiated coverage on Kite Pharma Inc (NASDAQ:KITE) with a Buy rating and a price target of $87, which represents …
Kite Pharma Inc (NASDAQ:KITE), announced clinical biomarker data from patients with relapsed/refractory B cell malignancies treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy …
In a research report issued today, Canaccord Genuity analyst John Newman reiterated a Buy rating on Kite Pharma Inc (NASDAQ:KITE) with a price …
Kite Pharma Inc (NASDAQ:KITE) has been reiterated as a Buy at Canaccord Genuity by research analyst John Newman. The analyst reiterated a Buy rating on …
On January 5th, biopharmaceutical company Amgen Inc. (NASDAQ: AMGN) announced plans to collaborate with Kite Pharma (NASDAQ: KITE) on cancer treatments.
